Fzata Announces the Appointment of A New Board Member

HALETHORPE, Md., May 16, 2025 /PRNewswire/ -- Fzata, Inc. announced today the appointment of a new independent member to the board of directors. The new board member Gianna Arnold, JD, MS is counsel with Saul Ewing, LLP and CEO of NuMoon Technologies, LLC. Gianna is a veteran corporate and transactional attorney with deep biopharma expertise, bringing to the board extensive experience in negotiating strategic alliances as well as conducting due diligence analysis for mergers, acquisitions, licensing, and investments.

"Gianna has been instrumental on our business advisory committee, and her extensive transactional experience will be invaluable as we pursue strategic pharma partnerships and prepare for our next equity financing round." said Dr. Zhiyong Yang, Chairman and CEO of Fzata.

Ms. Arnold has assisted clients in the life sciences for over 30 years, providing IP and transactional services. She was named to The Best Lawyers in America list for Biotechnology and Life Sciences, 2016 to 2023, as well as Chambers USA "America's Leading Lawyers in Intellectual Property" list from 2016 to present. In addition, she brings valuable past experience as an entrepreneur and corporate executive at NuMoon.

"I am very excited to fill this position at Fzata and provide transactional insight," said Ms. Arnold. "I have worked extensively with the company CEO on corporate strategy since its spinout from the University of Maryland Baltimore. I have had the privilege of observing Fzata's remarkable growth and believe their oral biologics platform holds extraordinary potential to transform patient care."

About Fzata, Inc.: The Company has developed a next-generation oral biologics modality called Bioengineered Probiotic Yeast Medicines (BioPYM™). BioPYM utilizes live yeast to carry a DNA payload and functions as a "micro-factory" to produce therapeutic biologics directly in the GI. Fzata has a deep pipeline of yeast drug candidates for GI diseases and gut-health axis disorders. 

For additional Fzata information, visit www.fzata.com or follow us on LinkedIn.com/company/Fzata

For investment opportunities, licensing, co-development, or collaboration inquiries, please contact:

Elizabeth Smith, PhD MBA, Chief Business Officer, Fzata
E-mail: [email protected]

SOURCE Fzata, Inc.